{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:55:48Z","timestamp":1768787748991,"version":"3.49.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The purpose of the present meta-analysis was to compare the efficacy of rifaximin and nonabsorbable disaccharides (NADs) in hepatic encephalopathy (HE).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>After the registration of the present meta-analysis on INPLASY, all procedures were performed according to PRISMA 2020. Relevant literature was retrieved on PubMed, Embase, and the Cochrane Library up to September 5, 2021. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the enrolled studies, and Review Manager software (version 5.3) was used to analyze the clinical efficacy, blood ammonia and adverse effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Six studies with 559 patients were included in the present meta-analysis. There were no significant differences in the basic characteristics of the included studies. Analysis of the complete resolution of HE showed that rifaximin was better than NADs (risk ratio [RR]\u200a=\u200a1.87, 95% confidence interval [CI]\u200a=\u200a1.03\u20133.39, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.04). However, there were no significant differences in mental status (RR\u200a=\u200a1.04, 95% CI\u200a=\u200a0.92\u20131.18, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.53), blood ammonia level (standard mean difference\u200a=\u200a\u22120.02, 95% CI\u200a=\u200a\u22120.40\u20130.02, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.08), or drug adverse drug effects (OR\u200a=\u200a0.43, 95% CI\u200a=\u200a0.10\u20131.77, <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a56%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.24) between the rifaximin and NADs treatment groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Rifaximin is not superior to NADs in the treatment of HE.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028232","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T19:13:53Z","timestamp":1640286833000},"page":"e28232","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7998-5938","authenticated-orcid":false,"given":"Junxiong","family":"Cheng","sequence":"first","affiliation":[{"name":"College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, Chongqing, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafang","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sclences and Chinese Medicine, Southwest University, Chongqing, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfu","family":"Cao","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, Chongqing, PR China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqing","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, PR China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"05","DOI":"10.1007\/s40265-018-1018-z","article-title":"Hepatic encephalopathy: definition, clinical grading and diagnostic principles","volume":"79","author":"Weissenborn","year":"2019","journal-title":"Drugs"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cld.2020.01.012","article-title":"Minimal hepatic encephalopathy","volume":"24","author":"Karanfilian","year":"2020","journal-title":"Clin Liver Dis"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.3748\/wjg.v27.i22.3050","article-title":"Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis","volume":"27","author":"Moran","year":"2021","journal-title":"World J Gastroentero"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1515\/hsz-2021-0172","article-title":"Rapid metabolic and bioenergetic adaptations of astrocytes under hyperammonemia - a novel perspective on hepatic encephalopathy","volume":"402","author":"Zimmermann","year":"2021","journal-title":"Biol Chem"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/hep.31708","article-title":"The use of rifaximin in patients with cirrhosis","volume":"74","author":"Caraceni","year":"2021","journal-title":"Hepatology"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"07","DOI":"10.2165\/00003495-197204010-00003","article-title":"Lactulose: a review of its therapeutic and pharmacological properties with particular reference to ammonia metabolism and its mode of action of portal systemic encephalopathy","volume":"4","author":"Avery","year":"1972","journal-title":"Drugs"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/hepr.13045","article-title":"Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: a phase II\/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial","volume":"48","author":"Suzuki","year":"2018","journal-title":"Hepatol Res"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.mayocp.2013.11.009","article-title":"Management of hepatic encephalopathy in the hospital","volume":"89","author":"Leise","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"304","DOI":"10.14218\/JCTH.2017.00037","article-title":"Minimal hepatic encephalopathy in Indians: psychometric hepatic encephalopathy score and inhibitory control test for diagnosis and rifaximin or lactulose for its reversal","volume":"7","author":"Pawar","year":"2019","journal-title":"J Clin Transl Hepatol"},{"key":"R12-20250504","first-page":"22","article-title":"Effects of rifaximin versus nonabsorbable disaccharides in hepatic encephalopathy","volume":"1","author":"Zhuo","year":"2019","journal-title":"Gastro Hep"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"236963","DOI":"10.1155\/2013\/236963","article-title":"Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: a meta-analysis","volume":"2013","author":"Wu","year":"2013","journal-title":"Gastroenterol Res Pract"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ajg.2010.455","article-title":"Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial)","volume":"106","author":"Sidhu","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.3748\/wjg.v25.i36.5403","article-title":"Chinese guidelines on management of hepatic encephalopathy in cirrhosis","volume":"25","author":"Xu","year":"2019","journal-title":"World J Gastroentero"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-8278(02)00350-1","article-title":"Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial","volume":"38","author":"Mas","year":"2003","journal-title":"J Hepatol"},{"key":"R17-20250504","first-page":"677","article-title":"Evaluation of rifaximin in management of hepatic encephalopathy","volume":"44","author":"Wahib","year":"2014","journal-title":"J Egypt Soc Parasitol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2478\/jtim-2020-0034","article-title":"Hepatic encephalopathy: diagnosis and management","volume":"8","author":"Ridola","year":"2021","journal-title":"J Transl Int Med"},{"key":"R19-20250504","first-page":"750","article-title":"Cost-effectiveness of rifaximin treatment in patients with hepatic encephalopathy","volume":"26","author":"Jesudian","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1080\/03007995.2018.1499506","article-title":"Evaluation of the cost-effectiveness of rifaximin-for the management of patients with hepatic encephalopathy in the United Kingdom","volume":"34","author":"Berni","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/13696998.2021.1877148","article-title":"Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States","volume":"24","author":"Volk","year":"2021","journal-title":"J Med Econ"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"e0186120","DOI":"10.1371\/journal.pone.0186120","article-title":"Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients","volume":"12","author":"Chang","year":"2017","journal-title":"PLoS One"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jinf.2010.11.004","article-title":"Rifaximin intake leads to emergence of rifampin-resistant staphylococci","volume":"62","author":"Valentin","year":"2011","journal-title":"J Infect"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1128\/AAC.00548-13","article-title":"Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile","volume":"57","author":"Huang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/cid\/cix918","article-title":"Breakthrough Clostridium difficile infection in cirrhotic patients receiving rifaximin","volume":"66","author":"Elena","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"e14807","DOI":"10.1111\/ijcp.14807","article-title":"Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus-related cirrhosis","volume":"75","author":"Abdel Moneim","year":"2021","journal-title":"Int J Clin Pract"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:07:53Z","timestamp":1746338873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028232"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":26,"journal-issue":{"issue":"51","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028232","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"assertion":[{"value":"2021-09-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}